Ania Jastreboff, M.D., Ph.D.

Stories

Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks

Directs the Yale Obesity Research Center (Y-Weight)

People on the highest dose of Eli Lilly's experimental obesity drug lost an average of 30.3% of their body weight over 104 weeks — a result doctors previously saw almost only after bariatric surgery. The finding comes from TRIUMPH-1, a Phase 3 trial that randomized 2,339 adults with obesity or overweight to one of three doses of retatrutide or a placebo.

Updated Yesterday

Notable Quotes

It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30% of their body weight over two years.

from Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks · Updated Yesterday

For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory.

from Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks · Updated Yesterday